Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.41
$3.51
$3.96
$12.00
$6.11M1.557,305 shs284 shs
IBT
IBEX Technologies
C$1.44
C$1.44
C$0.75
C$1.45
C$35.54M-0.0568,888 shs200 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$12.26
-1.7%
$11.43
$4.81
$27.50
$409.28MN/A257,472 shs22,203 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.05
+11.1%
C$0.04
C$0.04
C$0.10
C$9.90M0.7168,681 shs93,500 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%+2.10%-8.33%+33.18%-28.21%
IBT
IBEX Technologies
0.00%0.00%0.00%0.00%0.00%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
0.00%+16.05%+9.72%+107.92%+1,247,499,900.00%
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00%+25.00%+25.00%+11.11%-16.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/AN/AN/AN/A
IBT
IBEX Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.077 of 5 stars
3.50.00.00.02.73.30.6
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
IBT
IBEX Technologies
0.00
N/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.50205.77% Upside
Resverlogix Corp. stock logo
RVX
Resverlogix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RVX, MBX, IBT, and AEZS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00 ➝ $44.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$38.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.58N/AN/A$14.99 per share0.23
IBT
IBEX Technologies
C$5.77M6.15C$0.92 per share1.56C$0.58 per share2.48
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.23) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)
IBT
IBEX Technologies
C$3.10MC$0.1211.52N/A53.78%21.95%6.42%N/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$2.81M-C$0.02N/AN/AN/A6.06%-34.90%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
IBT
IBEX Technologies
N/A3.11%N/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A7.02%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
IBT
IBEX Technologies
11.06
6.24
4.93
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
-10.95
0.13
0.04

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
IBT
IBEX Technologies
19.05%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.10%
IBT
IBEX Technologies
25.36%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Resverlogix Corp. stock logo
RVX
Resverlogix
42.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
IBT
IBEX Technologies
N/A24.68 millionN/ANot Optionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
19197.94 millionN/ANot Optionable

Recent News About These Companies

Resverlogix Corp. (RVXCF)
Closing Bell: Resverlogix Corp up on Tuesday (RVX)
Closing Bell: Resverlogix Corp flat on Wednesday (RVX)
Resverlogix Corp. (RVX.TO)
Resverlogix Announces Change to Its Board of Directors
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
Resverlogix Corp. (RVX) Earnings Dates & Reports
Resverlogix Corp RVXCF
Resverlogix Corp RVX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

$3.41 0.00 (0.00%)
As of 07/3/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

IBEX Technologies CVE:IBT

C$1.44 0.00 (0.00%)
As of 04/5/2024

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$12.26 -0.21 (-1.65%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Resverlogix stock logo

Resverlogix TSE:RVX

C$0.05 +0.01 (+11.11%)
As of 07/4/2025 03:56 PM Eastern

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.